Skip to main content

RAD December 2021 Conference Abstracts and Posters

All accepted abstracts will be published in the British Journal of Dermatology.

658 - A Digital Therapeutic Solution for Atopic Dermatitis; Protocol for a Nonrandomized, Single-Arm, Interventional Trial

Gudmundsdottir SL, Eysteinsdottir J, Þorleifsdottir RH, Ulfsdottir H, Reykdal E, Hrafnkelsdottir SK, Bragadottir HB, Oddsson S, Silverberg J


659 - Protocol for an Ongoing, Phase 3 Multicenter, Long-Term Extension Study Investigating the Long-Term Safety and Efficacy of Abrocitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (JADE EXTEND)

Eric L. Simpson, Kristian Reich, Jonathan I. Silverberg, Adnan Nasir, Paulo Ricardo Criado, Pinaki Biswas, Herwig Koppensteiner, Dorothy Fan, Ricardo Rojo, Saleem A. Farooqui


663 - Efficacy and Safety of Dupilumab in Children Aged 6–11 Years with Inadequately Controlled Severe Atopic Dermatitis: Results From an Open-Label Extension Trial up to 1 Year

Amy S. Paller, Michael J. Cork, Elaine C. Siegfried, Emma Guttman-Yassky, Eric L. Simpson, Weily Soong, Jing Xiao, Zhixiao Wang, Chien-Chia Chuang, John T. O’Malley, Ashish Bansal


664 - Dupilumab Monotherapy for 1 Year Provides Sustained Improvement in DLQI in Adults With Moderate-to-Severe Atopic Dermatitis Optimally Responding at Week 16

Jerry Bagel, Servando E. Marron, Jean-Philippe Lacour, Andreas Pinter, Marco Romanelli, Chih-ho Hong, Hiroshi Mitsui, Chun Wook Park, Haixin Zhang, Ryan B. Thomas, Gaëlle Bégo Le-Bagousse, Genevieve Wortzman-Show, Ana B. Rossi


665 - Achieving a Deep Response on Patient-Reported Outcomes with Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Results From Three Phase 3 Trials

Raj Chovatiya, MD, PhD; Marie-Louise Schuttelaar, MD, PhD; Brian Calimlim, DrPH, MS; Yingyi Liu, PhD; Shunya Takemoto, MD; Sonja Ständer, MD


666 - Patient Preferences for Features of Systemic Atopic Dermatitis Therapies: A Discrete-Choice Experiment Study

Shawn Kwatra, Peter Lio, Brian Calimlim, Barry Ladizinski, Joel Davis, Willings Botha, Carol Mansfield, Stephan Weidinger


667 - Long-term Dupilumab Efficacy is Sustained in Adults with Moderate-to-Severe Atopic Dermatitis Transitioning From Weekly to Every Other Week Dosing: Results From an Open-Label Extension Trial

Mette Deleuran, H. Chih-ho Hong, David N. Adam, Iftikhar Hussain, Haixin Zhang, Arsalan Shabbir, Ainara Rodríguez Marco, Noah A. Levit


668 - Dupilumab Provides Long-Term Efficacy for up to 4 Years in an Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis

Jacob P. Thyssen, Andrew Blauvelt, Benjamin Lockshin, Ryszard Galus, Charles Lynde, Jing Xiao, Noah A. Levit, Ainara Rodríguez Marco, Arsalan Shabbir


669 - Long-Term Safety Data for Dupilumab up to 4 Years in an Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis

Andreas Wollenberg, Weily Soong, Melinda Goooderham, Robert Bissonnette, Jing Xiao, Faisal A. Khokhar, Ainara Rodríguez Marco, Noah A. Levit, Arsalan Shabbir


670 - Burden of Atopic Dermatitis in Infants/Preschoolers From EPI-CARE: An International Survey

Stephan Weidinger, Eric L. Simpson, Jonathan I. Silverberg, Sebastien Barbarot, Ana B. Rossi, Lysel Brignoli, Laurent Eckert, Ryan B. Thomas, Gaelle Bego-Le-Bagousse, Ashish Bansal, Jianyi Lee, Chien-Chia Chuang


Page 5 of 7
Results 41 - 50 of 66